Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer

MORRISVILLE, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today the appointment of Marc S. Rudoltz, M.D. to the newly created position of Chief Medical Officer. Dr. Rudoltz will oversee the development of the company’s novel therapies for oncology and infectious disease, including VT-1161 and VT-464. VT-1161 is an orally-administered, small molecule therapy in human clinical studies for the treatment of a range of fungal infections including onychomycosis. VT-464 is an orally-administered, small molecule therapy for the treatment of castration-refractory prostate cancer.

“We are excited to have Dr. Rudoltz join the Viamet team. He will play a critical role as we transition from a discovery-stage company to a product-focused company”

“We are excited to have Dr. Rudoltz join the Viamet team. He will play a critical role as we transition from a discovery-stage company to a product-focused company,” stated Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet Pharmaceuticals. “Marc brings more than 20 years of clinical and pharmaceutical development experience to Viamet, having served in senior capacities with several pharmaceutical companies and as a practicing oncologist. His impressive credentials and industry experience make him the ideal individual to lead our clinical development efforts.”

Dr. Rudoltz has extensive global experience in clinical, medical and regulatory affairs, including the successful development and execution of clinical programs from Phases 1 through 4. Previously, Dr. Rudoltz was Senior Global Clinical Leader at Novartis Oncology where he oversaw clinical development activities for both Glivec^® and Tasigna^®. Prior to Novartis, Dr. Rudoltz held senior clinical development positions with GPC Biotech, Enzon Pharmaceuticals and Berlex Laboratories. Dr. Rudoltz received his B.S. from the Massachusetts Institute of Technology and M.D. from SUNY Upstate Medical University.

“The ability of Viamet’s novel Metallophile^® Technology to deliver potent and selective inhibitors of clinically important metalloenzymes is very impressive,” stated Dr. Rudoltz. “Both VT-1161 and VT-464 appear to be best-in-class agents against their respective metalloenzyme targets. I look forward to working with the Viamet team to advance these and other compounds through clinical development and ultimately to the market.”

About Viamet Pharmaceuticals, Inc. (www.viamet.com)

Viamet discovers and develops novel, best-in-class inhibitors of key metalloenzymes via an innovative and proprietary metal-binding approach, the Metallophile^® Technology. Viamet’s disruptive Metallophile^® Technology is based on our leading expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to identify metalloenzyme targets with high therapeutic and commercial potential, leverage existing metalloenzyme inhibitors as the basis for our novel analogs, and rapidly generate superior compounds by optimizing the metal-binding component of existing inhibitors. Viamet is based in the Research Triangle Park region of North Carolina, USA.